Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
NewLimit has raised $435 million and accelerated its lead epigenetic reprogramming therapy into human trials next year—a timeline compressed from over a decade away due to unexpectedly compelling preclinical data in liver cells. The approach targets aging at the cellular level to restore function rather than halt time, positioning epigenetic intervention as a potential foundation for addressing multiple age-related diseases simultaneously.
AEON Clinic in Dubai offers physician-supervised IV nutrient therapies and NAD+ treatments as part of a broader shift toward personalized health optimization focused on healthspan rather than lifespan. The clinic positions these interventions within longer-term health strategies rather than as standalone wellness experiences, reflecting emerging sophistication in how longevity medicine is being integrated into clinical practice.
Elecoglipron (AZD5004/ECC5004), an oral once-daily GLP-1 receptor agonist developed by Eccogene and AstraZeneca, will present Phase 1b and Phase 2b clinical trial data at the American Diabetes Association Scientific Sessions in June 2026. The candidate targets weight loss and type 2 diabetes management with the practical advantage of no food or water restrictions.
Kailera Therapeutics is advancing ribupatide injection (KAI-9531), a once-weekly GLP-1/GIP dual agonist in Phase 3 trials for obesity treatment, with company leadership presenting clinical updates at the June 2026 Jefferies conference. The candidate represents one of several GLP-1-based mechanisms in development aimed at addressing weight regulation across different patient populations and delivery preferences.
Mayrlife Medical Health Resort has developed a structured lifestyle integration program for individuals already using GLP-1 medications, combining personalized nutrition, movement conditioning, and recovery protocols to address the metabolic and compositional changes that occur during pharmacologically-assisted weight loss. The program targets a critical gap: sustaining weight loss outcomes and preserving lean mass after GLP-1 initiation, rather than treating medication use in isolation.
Eisai and CaringKind have launched Magnolia Meals at Home for Alzheimer's disease and related dementias, providing brain-healthy recipes, meal planning, and nutritional guidance tailored to disease progression. The program addresses a documented gap in nutritional support for a population of 7.4 million Americans, grounded in evidence linking dietary intervention to cognitive outcomes.
Five finalists selected for The Longevity Show's inaugural pitch competition represent a conceptual shift in the longevity sector—from single-intervention therapies to integrated systems spanning therapeutics, nutrition, microbiome science, and healthcare access. The cohort signals movement toward infrastructure that supports healthspan across diverse populations and geographies.
Regenerative medicine is advancing from theoretical to practical application in liver repair, with organoid technology and engineered tissues now enabling researchers to reconstruct damaged liver tissue and potentially restore function. This represents a fundamental shift from managing liver decline to actively rebuilding organ structure—a capability with significant implications for extending healthspan in aging populations.
Clinical translation of aging interventions has accelerated substantially, with multiple therapies targeting root causes of age-related disease now in or approaching human trials. The field demonstrates measurable progress across cardiovascular, neurological, immune, and metabolic pathways that directly address mechanisms of aging rather than symptomatic disease management.
Researchers developed the Liver Aging Index (LAI), a noninvasive biomarker combining clinical measurements, plasma markers, and imaging data to assess biological liver aging independent of chronological age. The LAI predicted all-cause mortality and liver-related events more accurately than age alone across three large independent cohorts, with accelerated liver aging conferring 22–85% higher mortality risk per standard deviation increase.
Resbiotic's at-home microbiome test uses shotgun metagenomic sequencing to provide consumers with research-grade data on gut bacterial composition, diversity, and inflammation markers. The tool addresses a significant gap between symptom experience and actionable diagnostic information, positioning microbiome assessment as foundational to personalized longevity strategies.
Cardiovascular health deteriorates significantly during perimenopause, with women in this transition phase showing twice the odds of poor cardiometabolic scores compared to premenopausal women. This critical window presents an opportunity for early intervention before postmenopausal decline solidifies, particularly through metabolic monitoring and dietary optimization.